Privately, I’ve diagramed how the Anavex molecules might work against a number of non-CNS diseases. I won’t post any of those here. To do so would simply prompt a bunch of “Ridiculous. Can’t be so!” pronouncements. But, Missling knows. In a year or two, after approval of one or two of the Anavex drugs, revenues will allow for expanded, diverse clinical trials in humans, against a variety of diseases and conditions.
The elder populations that will be receiving A2-73 will also have a host of other age related problems and if statistics show improvements in other pathologies, then it will be like a parent waiting for a child to see the light in a simple problem.